Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

PERKIN ELMER CORPORATION

PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App





Researchers Develop Cheaper, Rapid, and Accurate Pooling Strategy for RT-PCR-Based Detection of SARS-CoV-2

By LabMedica International staff writers
Posted on 03 Aug 2020
A team of researchers have developed a cheaper, rapid, and accurate pooling strategy for the RT-PCR-based detection of SARS-CoV-2 in clinical samples that could have a significant impact on large-scale population screening in the wake of the current COVID-19 pandemic.

Researchers at the Medical College of Georgia at Augusta University (Augusta, GA, USA) and PerkinElmer Genomics (Pittsburgh, PA, USA) have proposed a mass population screening approach based on sample pooling strategy for rapid and wide-scale population screening that can be adopted by laboratories currently using RT-PCR–based methods to test for SARS-CoV-2. More...
The researchers estimate that the strategy could lead to an approximately 5- to 10-fold reduction in the cost of testing of SARS-CoV-2. The global impact of these enormous savings has the potential to enhance laboratory operations throughout the pandemic and can be deployed to laboratories that are facing dire constraints in supplies.

The researchers tested the strategy by analyzing approximately 1,000 samples using their pooled sampling approach and achieved 91.6% PPA (positive percent agreement) and 100% NPA (negative percent agreement) as compared to the routine screening approach. The study demonstrates the clinical utility and accuracy of sample pooling strategy and presents a carefully planned layout for mass population testing that can be executed by laboratories using RT-PCR–based methods for detecting SARS-CoV-2. The proposed methodology has the potential to allow institutions to ramp up their testing needs in a cost-efficient manner with minimal turnaround times. This testing allows for the timely isolation and treatment of COVID-19–positive patients, specifically in populations with a lower prevalence of the disease, for example, screening large numbers of students returning to college campuses.

“In terms of cost analysis, one million individuals can be tested for around USD 9.1 million with the proposed mass population screening approach compared to approximately USD 58 million with current routine diagnostic methods. These cost projections highlight significant savings of healthcare dollars that could be achieved in both high- and low/middle-income countries,” said Amyn Rojiani, MD, PhD, Chair of the MCG Department of Pathology.

Related Links:

Platinum Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 TEST READER
COVID-19-CHECK-1 EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.